CJA
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text (PDF)
Right arrow Submit a scholarly reply
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fujii, Y.
Right arrow Articles by Toyooka, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fujii, Y.
Right arrow Articles by Toyooka, H.

Canadian Journal of Anesthesia, Vol 44, 273-277, Copyright © 1997 by Canadian Anesthesiologists' Society

ARTICLES

Prophylactic antiemetic efficacy of granisetron in patients with and without previous postoperative emesis

Y Fujii, H Tanaka and H Toyooka
Department of Anaesthesiology, Toride Kyodo General Hospital, Ibaraki, Japan.

PURPOSE: To evaluate the efficacy of granisetron, a selective antagonist of 5-hydroxytryptamine type 3 receptors, in the prevention of PONV in patients with and without previous postoperative emesis undergoing general anaesthesia for major gynaecological surgery. METHODS: In a randomized, double-blind, placebo-controlled trial of 90 women with (n = 40) and without (n = 50) a history of PONV, the patients received either granisetron (40 micrograms.kg-1) or placebo (saline) iv immediately before induction of anaesthesia. The same standard general anaesthetic technique, which consisted of isoflurane in nitrous oxide and oxygen and avoided opioids, was used. Nausea, vomiting and safety assessments were performed during the first 24 hr after anaesthesia. RESULTS: The incidence of PONV was 70% and 25% after administration of placebo and granisetron in patients with previous PONV (P ] 0.05), and was 40% and 8% in patients without it, respectively (P < 0.05). The incidence of adverse events postoperatively were not different among the treatment groups. CONCLUSION: Granisetron 40 micrograms.kg-1 given prior to anaesthesia reduces the incidence of PONV in patients with a history of PONV as well as in patients without it.


This article has been cited by other articles:


Home page
 Canadian J. AnesthesiaHome page
I. Henzi, J. Sonderegger, and M. R. Tramer
Efficacy, dose-response, and adverse effects of droperidol for prevention of postoperative nausea and vomiting
Can J Anesth, June 1, 2000; 47(6): 537 - 551.
[Abstract] [Full Text] [PDF]

Home page
 Anesth. Analg.Home page
P. Kranke, C. C. Apfel, N. Roewer, and Y. Fujii
Reported Data on Granisetron and Postoperative Nausea and Vomiting by Fujii et al. Are Incredibly Nice! • Response
Anesth. Analg., April 1, 2000; 90(4): 1004 - 1007.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1997 by the Canadian Anesthesiologists' Society.